দেশ: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
GENMED A DIVISION OF PFIZER CANADA ULC
N06AX23
DESVENLAFAXINE
50MG
TABLET (EXTENDED-RELEASE)
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50MG
ORAL
7/14/28/30/90
Prescription
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0152509001; AHFS:
CANCELLED PRE MARKET
2020-04-02
PRODUCT MONOGRAPH Pr GD * -DESVENLAFAXINE Desvenlafaxine Succinate Extended Release Tablets 50 and 100 mg desvenlafaxine as desvenlafaxine succinate Antidepressant GenMed, a Division of Pfizer Canada Inc. 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Preparation: January 24, 2018 Submission Control No.: 212741 * GD is a trademark of Pfizer Canada Inc. GenMed, a division of Pfizer Canada Inc., Licensee © Pfizer Canada Inc. 2017 _GD-Desvenlafaxine (desvenlafaxine succinate) Product Monograph _ _Page 2 of 51 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION................................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................12 DRUG INTERACTIONS ....................................................................................................22 DOSAGE AND ADMINISTRATION ................................................................................26 OVERDOSAGE ...................................................................................................................29 ACTION AND CLINICAL PHARMACOLOGY ...............................................................31 STORAGE AND STABILITY ............................................................................................35 SPECIAL HANDLING INSTRUCTIONS ..........................................................................35 DOSAGE FORMS, COMPOSITION AND PACKAGING ................................................35 PART II: SCIENTIFIC INFORMATION ..................... সম্পূর্ণ নথি পড়ুন